Uncertainty is the constant in today’s market. Ongoing Covid flare-ups, inflation, supply chain disruptions and now war are further intensifying an already volatile mix that’s spooking markets.
To reduce exposure to volatile market movements, investors are considering more defensive strategies. Classic defensive sectors furnish essential goods and services which consumers are unlikely to give up even in a downturn. With a steady focus on ‘healthy essentials’, RobecoSAM Sustainable Healthy Living is a thematic equity strategy that typically outperforms in down market cycles while still capturing the upside potential provided by long-term growth trends.
Amid general market misery, thematics with defensive characteristics are faring much better than other growth-focused strategies
Amid general market misery, thematics with defensive characteristics are faring much better than other growth-focused strategies. As David Kägi, portfolio manager for the RobecoSAM Sustainable Healthy Living Equities strategy, explains, “Defensive sectors generally provide stable earnings that are uncorrelated with the overall stock market. They even tend to outperform when broader markets are falling.”
Kägi credits his strategy’s less volatile, risk-adjusted performance with its strong tilt towards healthcare and consumer staples sectors. Together these account for around two-thirds of the portfolio. “Consumer staples stocks function in a noncyclical manner, meaning they offer investors safety during recessionary climates. Food, grooming and cleaning products are typical staples that tend to generate solid profits even in slow-growth economies.” He notes consumer staples companies thrived during the pandemic’s early stages when markets overall were tanking.
Stable, risk-adjusted performance comes from a strong tilt towards healthcare and consumer staples sectors
Meanwhile, he describes his other defensive allocation, healthcare, as a perennial pursuit. “Demand for healthcare services is inelastic. People don’t ignore their health because of a dip in the business cycle. Healthcare stocks can expand earnings even in down markets.” He references healthcare costs in the US which are nearly 18% of GDP and says that globally, healthcare expenditures are rising, approaching USD 10 trillion annually.
He adds that more stable performance returns, many defensive stocks pay substantial dividends which have reliably increased through past market cycles. Their longevity is a strong signal of a high-quality stock backed by strong consumer trust, brand value, and good management. These same attributes also help staples navigate the changing challenges across economic cycles.
Early on in the pandemic as markets were falling, many segments of healthcare were resilient and displayed strong performance, from sophisticated biotech and pharmaceuticals churning out vaccines to makers of protective gear. Stocks of diagnostic and testing equipment benefited as well. Moreover, Kägi says pandemic pressures accelerated digitalization trends in healthcare, which has historically been slow to adopt new technologies. From vaccine development and clinical trials to telemedicine and health tracking apps, the pandemic catalyzed new avenues of growth across the healthcare supply chain. He is certain that new revenue channels will continue to grow even as the virus abates.
In consumer staples, he says demand for hygienic items like hand soap, disinfectants and anti-microbial wipes surged, as did over-the-counter retail medications and home remedies to relieve viral symptoms. Here too he is convinced that many Covid-induced attitudes and behavioral changes will stick post-pandemic, providing steady returns for the Strategy’s defensive stocks and clusters.
Also underpinning the Strategy’s long-term growth potential are its focus on sustainability challenges that transcend market movements and mayhem over the longer term. “Society is confronting a series of serious health-related issues from rising healthcare costs and aging populations to the increasing prevalence of chronic illness.” He’s confident investments in preventative measures such as good nutrition and staying active will help reduce disease rates and curb healthcare’s cost creep.
Kägi says a focus on health across the entire human lifespan sets the portfolio apart from other healthcare theme strategies that tend to be treatment oriented. “We’re investing in companies that promote healthy living early on so that populations remain active and healthy well beyond retirement.” The Strategy’s convictions on shifts in consumer spending and preferences are so far spot on, as healthy changes in the UK’s consumer price index demonstrate. Donuts and men’s suits are out while lentils and sports bras are in.
The portfolio maintains a low beta coefficient, a key measure of its sensitivity to market fluctuations, as well as low absolute volatility, which means returns have avoided wild swings relative to broader markets (see Table 1).
Meanwhile, solid risk-adjusted performance is also demonstrated in solid upside and downside capture ratios. The Strategy’s downside capture ratio was 0.70, meaning it has reduced the portfolio’s exposure to market losses by 30%. Meanwhile, its upside capture ratio over the same time period stands at 0.78, meaning it has captured nearly 80% of the positive returns generated when markets are rising.
For conservative investors seeking solid performance without the volatility, the Strategy presents an interesting alternative. Its tilt towards noncyclical sectors helps reduce exposure to losses in down market cycles while its unique approach to rising healthcare costs allows it to benefit from long-term sociodemographic shifts already underway. For growth-oriented investors, it provides active exposure to diagnostic and digital innovation that’s opening new frontiers in health maintenance and delivery for patients and health-conscious consumers. With these features, it’s well suited for investors concerned as much with the journey as the destination.
1Gross of fees performance in EUR for the RobecoSAM Sustainable Healthy Living Equities Strategy as of 31.12.2021.
The currency in which the past performance is displayed my differ from the currency of your country of residence. Due to exchange rate fluctuations, the performance shown may increase or decrease if converted into your local currency. Periods shorter than one year are not annualized. The value of your investments may fluctuate. Past performance is no guarantee of future results. Returns gross of fees, based on gross asset value. Values and returns indicated here are before cost; neither consider the management fee as well as other administration costs related to the strategy nor the fees and costs which may be charged when subscribing, redeeming and or switching units. These have a negative effect on the returns shown. Effective October 29, 2020, select RobecoSAM equity strategies were merged onto the RCGF SICAV platform and received new inception dates, share classes, and ISIN codes. All performance prior to the RCGF SICAV merger have been calculated based on the investment policies, fees and share classes of the respective sub-strategy under the previous SICAV.
The contents of this document have not been reviewed by the Securities and Futures Commission ("SFC") in Hong Kong. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. This document has been distributed by Robeco Hong Kong Limited (‘Robeco’). Robeco is regulated by the SFC in Hong Kong.
This document has been prepared on a confidential basis solely for the recipient and is for information purposes only. Any reproduction or distribution of this documentation, in whole or in part, or the disclosure of its contents, without the prior written consent of Robeco, is prohibited. By accepting this documentation, the recipient agrees to the foregoing
This document is intended to provide the reader with information on Robeco’s specific capabilities, but does not constitute a recommendation to buy or sell certain securities or investment products. Investment decisions should only be based on the relevant prospectus and on thorough financial, fiscal and legal advice. Please refer to the relevant offering documents for details including the risk factors before making any investment decisions.
The contents of this document are based upon sources of information believed to be reliable. This document is not intended for distribution to or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.
Investment Involves risks. Historical returns are provided for illustrative purposes only and do not necessarily reflect Robeco’s expectations for the future. The value of your investments may fluctuate. Past performance is no indication of current or future performance.
Please read this information carefully.
This website is prepared and issued by Robeco Hong Kong Limited ("Robeco"), which is a corporation licensed by the Securities and Futures Commission in Hong Kong to engage in Type 1 (dealing in securities); Type 4 (advising in securities) and Type 9 (asset management) regulated activities. The Company does not hold client assets and is subject to the licensing condition that it shall seek the SFC’s prior approval before extending services at retail level. This website has not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong.
2. Important risk disclosures
2. Important risk disclosures Robeco Capital Growth Funds (“the Funds”) are distinguished by their respective specific investment policies or any other specific features. Please read carefully for the risks of the Funds:
3. Local legal and sales restrictions
The information contained in the Website is being provided for information purposes.
Neither information nor any opinion expressed on the Website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. The information contained in the Website does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, most recent annual and semi-annual reports, which can be all be obtained free of charge at www.robeco.com/hk/en and at the Robeco Hong Kong office.
4. Use of the Website
The information is based on certain assumptions, information and conditions applicable at a certain time and may be subject to change at any time without notice. Robeco aims to provide accurate, complete and up-to-date information, obtained from sources of information believed to be reliable. Persons accessing the Website are responsible for their choice and use of the information.
5. Investment performance
No assurance can be given that the investment objective of any investment products will be achieved. No representation or promise as to the performance of any investment products or the return on an investment is made. The value of your investments may fluctuate. The value of the assets of Robeco investment products may also fluctuate as a result of the investment policy and/or the developments on the financial markets. Results obtained in the past are no guarantee for the future. Past performance, projection, or forecast included in this Website should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Fund performance figures are based on the month-end trading prices and are calculated on a total return basis with dividends reinvested. Return figures versus the benchmark show the investment management result before management and/or performance fees; the fund returns are with dividends reinvested and based on net asset values with prices and exchange rates of the valuation moment of the benchmark.
Investments involve risks. Past performance is not a guide to future performance. Potential investors should read the terms and conditions contained in the relevant offering documents and in particular the investment policies and the risk factors before any investment decision is made. Investors should ensure they fully understand the risks associated with the fund and should also consider their own investment objective and risk tolerance level. Investors are reminded that the value and income (if any) from shares of the fund may be volatile and could change substantially within a short period of time, and investors may not get back the amount they have invested in the fund. If in doubt, please seek independent financial and professional advice.
6. Third party websites
This website includes material from third parties or links to websites maintained by third parties some of which is supplied by companies that are not affiliated to Robeco. Following links to any other off-site pages or websites of third parties shall be at the own risk of the person following such link. Robeco has not reviewed any of the websites linked to or referred to by the Website and does not endorse or accept any responsibility for their content nor the products, services or other items offered through them. Robeco shall have no liability for any losses or damages arising from the use of or reliance on the information contained on websites of third parties, including, without limitation, any loss of profit or any other direct or indirect damage. Third party off-site pages or websites are provided for informational purposes only.
7. Limitation of liability
Robeco as well as (possible) other suppliers of information to the Website accept no responsibility for the contents of the Website or the information or recommendations contained herein, which moreover may be changed without notice.
Robeco assumes no responsibility for ensuring, and makes no warranty, that the functioning of the Website will be uninterrupted or error-free. Robeco assumes no responsibility for the consequences of e-mail messages regarding a Robeco (transaction) service, which either cannot be received or sent, are damaged, received or sent incorrectly, or not received or sent on time.
Neither will Robeco be liable for any loss or damage that may result from access to and use of the Website.
8. Intellectual property
All copyrights, patents, intellectual and other property, and licenses regarding the information on the Website are held and obtained by Robeco. These rights will not be passed to persons accessing this information.
10. Applicable law
The Website shall be governed by and construed in accordance with the laws of Hong Kong. All disputes arising out of or in connection with the Website shall be submitted to the exclusive jurisdiction of the courts of Hong Kong.